Table 1 Baseline characteristics.
Patients (n = 175) | |
|---|---|
Age, years | |
Median(IQR) | 45 (34–54) |
< 20 | 5 (2.9%) |
20–29 | 23 (13.1%) |
30–39 | 35 (20.0%) |
40–49 | 44 (25.1%) |
50–59 | 68 (28.9%) |
Sex | |
Male | 74 (42.3%) |
Female | 101 (57.7%) |
Baseline bone marrrow blast cell proportion, % | |
Median (IQR) | 56 (34.2–74.8%) |
< 30% | 34 (19.4%) |
≥ 30% to < 50% | 38 (21.7%) |
≥ 50% | 103 (58.8%) |
Baseline peripheral white blood cell count, x 109/L | |
Median(IQR) | 15.7 (5.9–48.5) |
< 10 | 66 (37.7%) |
≥ 10 to < 40 | 57 (32.6%) |
≥ 40 to < 100 | 33 (18.9%) |
≥ 100 | 19 (10.8%) |
Selected molecular mutation | |
FLT3-ITD | 40 (22.9%) |
NPM1 | 31 (17.7%) |
DNMT3A | 24 (13.7%) |
CEBPA | 24 (13.7%) |
TET2 | 14 (8%) |
ASXL1 | 12 (6.9%) |
IDH1 | 9 (5.1%) |
IDH2 | 8 (4.6%) |
TP53 | 3 (1.7%) |
BCR-ABL | 2 (1.1%) |
ELN2017 risk category | |
Favourable | 82 (46.9%) |
Intermediate | 65 (37.1%) |
Adverse | 28 (16.0%) |
Cytogenetic risk category | |
Favourable | 44 (25.2%) |
Intermediate | 102 (58.3%) |
Adverse | 16 (9.1%) |
No mitosis | 13 (7.4%) |
ELN 2022 risk category | |
Favourable | 79 (45.1%) |
Intermediate | 64 (36.6%) |
Adverse | 32 (18.3%) |
Induction therapy regimen | |
DA | 111 (63.4%) |
IA | 64 (36.6%) |
Allo-HSCT, n | 35 (20%) |
Re-induction therapy regimen of NR patients | |
Venetoclax + azacitidine | 9 |
Venetoclax + azacitidine + homoharringtonine | 3 |
FLAG/CLAG | 4 |
CAG | 2 |
HA | 2 |
